Concordance in histological and biological parameters between first and second primary breast cancers

Cancer

Volumn 117, Issue 5, 2011, Pages 907-915

  Huo, Dezheng ^a   Melkonian, Stephanie ^a   Rathouz, Paul J ^a   Khramtsov, Andrey ^a   Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Breast neoplasms; Estrogen receptor; Molecular epidemiology; Second primary neoplasm; Seer program; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY BREAST CANCER; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; MUCINOUS CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SECOND CANCER;

AGE FACTORS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS;

EID: 79952014494     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25587     Document Type: Article

References (24)

1. Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology. 2003;14:552-558. (Pubitemid 40417036)
2. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009;101:1058-1065.
3. Kollias J, Pinder SE, Denley HE, et al. Phenotypic similarities in bilateral breast cancer. Breast Cancer Res Treat. 2004;85:255-261. (Pubitemid 38987260)
4. Hahnel R, Twaddle E. The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas. Breast Cancer Res Treat. 1985;5:155-163. (Pubitemid 15124774)
5. Weitzel JN, Robson M, Pasini B, et al. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005;14:1534-1538. (Pubitemid 40807358)
6. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005;23:4687-4694. (Pubitemid 46224071)
7. Intra M, Rotmensz N, Viale G, et al. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer. 2004;101:905-912. (Pubitemid 39100421)
8. Coradini D, Oriana S, Mariani L, et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer. 1998;34:825-830.
9. Gong SJ, Rha SY, Jeung HC, Roh JK, Yang WI, Chung HC. Bilateral breast cancer: differential diagnosis using histological and biological parameters. Jpn J Clin Oncol. 2007;37:487-492. (Pubitemid 47335466)
10. Swain SM, Wilson JW, Mamounas EP, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst. 2004;96:516-523. (Pubitemid 38559575)
11. Holdaway IM, Mason BH, Bennett RC, Alexander AI, Hahnel R, Kiang DT. Estrogen receptors in bilateral breast cancer. Cancer. 1988;62:109-113.
12. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Limited-Use Data (1973-2007). Available at http://www.seer. cancer.gov/. Accessed September 29, 2010.
13. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
14. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721-7735. (Pubitemid 46291836)
15. Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002;94:1626-1634.
16. Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr. 2006;36:7-15.
17. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388. (Pubitemid 28439961)
18. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300. (Pubitemid 36126189)
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-3988. (Pubitemid 36418143)
20. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
21. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab. 2004;15:193-197. (Pubitemid 38833988)
22. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485. (Pubitemid 37279334)
23. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4:e1000054.
24. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon MS, et al. Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev. 2009;18:2214-2220.